Yep!!The pharma & biotech industry is seeing an increase in M&A activity for innovations in new modalities, which mirrors the priority of expediting drug delivery to patients. Sarah Holland, VP, Global Head of Licensing, joined a roundtable with Pharma's Almanac to discuss her insights into the M&A environment and what the future may hold for innovator biotechs and big pharma looking to acquire expertise in-house.
Market Data 
Markets 
AI
